INTEGRIS-PSC Phase 2 Results: Bexotegrast Shows Promise for Primary Sclerosing Cholangitis at AASLD 2024

Pliant Therapeutics Presents Clinical Data on Bexotegrast at The Liver Meeting 2024

Overview:
Pliant Therapeutics, Inc. announced the presentation of clinical data at The Liver Meeting 2024 in San Diego, California. The focus was on bexotegrast, an oral treatment aimed at fibrotic diseases.

Key Findings:

1. Bexotegrast Benefits:

   • Bexotegrast improved cholestasis symptoms.
   • It stabilized liver fibrosis markers in patients with primary sclerosing cholangitis (PSC).
   • Data showed positive results after 24 weeks from the Phase 2 INTEGRIS-PSC trial.

2. Presentation Highlights:

   • Dr. Kris Kowdley of the Liver Institute Northwest highlighted that bexotegrast was well tolerated and effective in reducing liver stiffness and improving liver biochemistry.
3. Novel Biomarkers Study:
   • In a poster presentation, Dr. Johanna Schaub presented new diagnostic biomarkers for PSC.
   • The study utilized proteomic screening, identifying several new potential biomarkers for PSC progression.

Company Background:
Pliant Therapeutics specializes in developing treatments for fibrotic diseases. Their lead product, bexotegrast (PLN-74809), is also being studied for idiopathic pulmonary fibrosis (IPF). The company has received Fast Track and Orphan Drug designations from the FDA for both IPF and PSC.

Conclusion:
The presentations at The Liver Meeting showcased promising progress in the treatment of PSC with bexotegrast. Pliant Therapeutics continues to advance its research and development in finding effective solutions for complex liver conditions. For more information, visit PliantRx.com.